Prognosis and Treatment of Metastatic Skin Cancers

DOI Web Site
  • Saito Yuki
    Division of Dermatology, Niigata Cancer Center Hospital Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences
  • Torai Ryotaro
    Division of Dermatology, Niigata Cancer Center Hospital Department of Dermatology, Graduate School of Medical and Pharmaceutical Sciences, University of Toyama
  • Takatsuka Sumiko
    Division of Dermatology, Niigata Cancer Center Hospital
  • Takenouchi Tatsuya
    Division of Dermatology, Niigata Cancer Center Hospital

Bibliographic Information

Other Title
  • 転移性皮膚癌の予後と治療―当センター260例の解析―
  • テンイセイ ヒフ ガン ノ ヨゴ ト チリョウ : トウ センター 260レイ ノ カイセキ

Search this article

Abstract

<p>We retrospectively investigated the clinical characteristics and prognosis in 260 cases of metastatic skin cancer. The common primary cancer sites were breast (86 cases, 33%) and lung (76 cases, 29%). In 17% of cases, skin metastases preceded the diagnosis of the original cancer.</p><p>The median survival time (MST) after the diagnosis of skin metastases was 7 months. MST for breast cancer (56 months) was significantly longer than in other cases because of its originally good prognosis. None of the prognostic factors, including the number of skin metastases (multiple vs single), the timing of cancer diagnosis (skin metastases vs primary cancer), and treatment for skin metastases (curative resection vs palliative resection) significantly affect survival. We condude that the main purpose for treating metastatic skin cancer is to maintain the quality of a patient's life.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top